Cardano Risk Management B.V. Has $94.28 Million Position in Amgen Inc. $AMGN

Cardano Risk Management B.V. lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 5.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 260,359 shares of the medical research company’s stock after selling 14,358 shares during the period. Cardano Risk Management B.V.’s holdings in Amgen were worth $94,281,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in AMGN. Vanguard Group Inc. boosted its holdings in shares of Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after purchasing an additional 961,975 shares in the last quarter. State Street Corp increased its stake in shares of Amgen by 4.4% in the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after purchasing an additional 1,287,310 shares during the last quarter. Capital World Investors raised its holdings in shares of Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after buying an additional 4,302,237 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after buying an additional 1,035,779 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Amgen during the 4th quarter worth $2,164,162,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Quarterly results exceeded expectations: Amgen reported second-quarter revenue of approximately $10.05 billion, up 9.5% year over year, while adjusted earnings of $6.29 per share surpassed the $5.62 consensus estimate. Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513
• Positive Sentiment: Guidance was raised: Management now expects fiscal-year earnings of $22.30 to $23.50 per share, supported by growth in cardiovascular, bone-health and rare-disease medicines. The performance offset pressure in the bone-health business and the decision to discontinue obesity candidate AMG 513. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Positive Sentiment: Analyst targets point to additional upside: BMO Capital Markets raised its target to $450, while UBS and TD Cowen set targets of $440 and $452, respectively. Morgan Stanley, RBC, Oppenheimer and Scotiabank also indicated that Amgen’s stock could rise. BMO Capital Markets Boosts Amgen Price Target to $450
• Neutral Sentiment: Analyst sentiment remains mixed: Wells Fargo raised its target to $400 and Canaccord Genuity to $384, both below the stock’s recent trading level, while Citi maintained a Hold rating and UBS maintained a Buy rating. This suggests strong results have improved sentiment, but valuation and pipeline execution remain concerns. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Pipeline disappointment limits the upside case: Amgen dropped AMG 513, its obesity-drug candidate, removing a potential growth driver and leaving investors focused on the company’s existing medicines and remaining pipeline. Amgen drops AMG 513

Amgen Price Performance

AMGN stock opened at $410.95 on Friday. The company has a market capitalization of $222.17 billion, a P/E ratio of 25.54, a PEG ratio of 3.83 and a beta of 0.41. The company has a fifty day moving average price of $362.77 and a 200-day moving average price of $356.24. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.01 and a current ratio of 1.37. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $418.40.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same quarter in the previous year, the firm posted $6.02 earnings per share. Amgen’s revenue for the quarter was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities analysts expect that Amgen Inc. will post 22.78 EPS for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.5%. Amgen’s payout ratio is presently 62.65%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Bank of America raised their price objective on Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research note on Wednesday. Truist Financial increased their target price on shares of Amgen from $340.00 to $362.00 and gave the stock a “hold” rating in a report on Wednesday. TD Cowen raised their price target on shares of Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research note on Wednesday. Argus decreased their price target on shares of Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a report on Wednesday, May 20th. Finally, Royal Bank Of Canada upped their price objective on shares of Amgen from $370.00 to $400.00 and gave the stock an “outperform” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and an average price target of $370.07.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.85% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.